These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 22512789)

  • 1. Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011).
    Probst G; Xu YZ
    Expert Opin Ther Pat; 2012 May; 22(5):511-40. PubMed ID: 22512789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
    Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
    J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BACE1 in Alzheimer's disease.
    Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
    Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
    Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
    Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
    Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
    J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
    Barão S; Moechars D; Lichtenthaler SF; De Strooper B
    Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as BACE1 inhibitors: a patent evaluation of WO2013041499.
    Dessolin J
    Expert Opin Ther Pat; 2014 Feb; 24(2):239-42. PubMed ID: 24219148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.
    Liang H; Shi Y; Kou Z; Peng Y; Chen W; Li X; Li S; Wang Y; Wang F; Zhang X
    PLoS One; 2015; 10(10):e0140733. PubMed ID: 26473367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease.
    Silvestri R
    Med Res Rev; 2009 Mar; 29(2):295-338. PubMed ID: 18651582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020).
    Rombouts F; Kusakabe KI; Hsiao CC; Gijsen HJM
    Expert Opin Ther Pat; 2021 Jan; 31(1):25-52. PubMed ID: 33006491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo.
    Atwal JK; Chen Y; Chiu C; Mortensen DL; Meilandt WJ; Liu Y; Heise CE; Hoyte K; Luk W; Lu Y; Peng K; Wu P; Rouge L; Zhang Y; Lazarus RA; Scearce-Levie K; Wang W; Wu Y; Tessier-Lavigne M; Watts RJ
    Sci Transl Med; 2011 May; 3(84):84ra43. PubMed ID: 21613622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, characterization, and PK/PD studies of a series of spirocyclic pyranochromene BACE1 inhibitors.
    Volgraf M; Chan L; Huestis MP; Purkey HE; Burkard M; Geck Do M; Harris J; Hunt KW; Liu X; Lyssikatos JP; Rana S; Thomas AA; Vigers GP; Siu M
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2477-80. PubMed ID: 24780121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Moussa CE
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iminoheterocycle as a druggable motif: BACE1 inhibitors and beyond.
    Zhu Z
    Trends Pharmacol Sci; 2012 May; 33(5):233-40. PubMed ID: 22480948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
    Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
    J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [BACE1 inhibitors for the treatment of Alzheimer disease].
    Tomita T
    Nihon Rinsho; 2016 Mar; 74(3):427-31. PubMed ID: 27025081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolution of amidine-based brain penetrant BACE1 inhibitors.
    Oehlrich D; Prokopcova H; Gijsen HJ
    Bioorg Med Chem Lett; 2014 May; 24(9):2033-45. PubMed ID: 24704031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress toward the discovery and development of efficacious BACE inhibitors.
    Durham TB; Shepherd TA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):776-91. PubMed ID: 17117686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease.
    Yuan J; Venkatraman S; Zheng Y; McKeever BM; Dillard LW; Singh SB
    J Med Chem; 2013 Jun; 56(11):4156-80. PubMed ID: 23509904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.